KRAS Inhibitor Resistance Confers a Targetable Vulnerability to Ferroptosis in Pancreatic Ductal Adenocarcinoma.
KRAS inhibitors represent a promising therapeutic frontier in pancreatic ductal adenocarcinoma (PDAC) treatment. However, the clinical benefit of KRAS inhibitors in PDAC is limited by the frequent emergence of resistance. Here, we demonstrated that acquisition of resistance to KRAS inhibitors rendered PDAC cells hypers...